Navigation Links
Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
Date:6/22/2011

here is a high unmet need for faster, more effective and safe antidepressants to help the millions of patients poorly served by current agents.  We look forward to reporting the results of this first assessment of the potential efficacy of GLYX-13 in patients with treatment-resistant depression during 2012."

In preclinical studies, GLYX-13 has demonstrated the robust antidepressant-like activity of ketamine, including its rapid onset and long duration of effect, with no signs of side effects.  It also achieved the widest therapeutic ratio between efficacy and side effects (>500:1) of any known NMDAR modulator.  

In a Phase I trial, GLYX-13 was well tolerated, with adverse events for the groups receiving GLYX-13 and placebo all rated as mild.  There were no signs of the schizophrenia-like side effects associated with other drugs that modulate the NMDAR.

For more information about the GLYX-13 Phase II trial, see http://clinicaltrials.gov/ct2/show/NCT01234558?term=glyx-13&rank=2.

About NaurexNaurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way -- Glycine-site Functional Partial Agonists (GFPAs).  In preclinical studies, Naurex's lead product, GLYX-13, has shown promising signs of rapid-acting, long-lasting antidepressant activity with excellent safety, and the safety results have been confirmed in a Phase I clinical trial.  Naurex is currently conducting a Phase II trial to assess GLYX-13 in patients who have had an inadequate response to an existing antidepressant treatment.  Naurex's second-generation program, which comprises novel patented GFPA chemistry classes with key molecular features, represents a platform for the development of new therapies for a va
'/>"/>

SOURCE Naurex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
2. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
3. Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™
4. American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4%, 30 mL Single Dose Vial Due to Particulates
5. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
6. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
7. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
8. American Regent Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter
9. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
10. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
11. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Ustekinumab ... in Nearly 2,000 Patients, HORSHAM, ... International NV announced today that regulatory,applications have been submitted requesting ... Europe for the treatment of adult,patients with chronic moderate to ...
... Phase III Open Label Trial Published in Online Edition ... ... Soliris(R),(eculizumab) therapy reduced hemolysis and improved fatigue, overall,quality of life and ... called paroxysmal nocturnal hemoglobinuria (PNH), according,to an analysis of the Phase ...
Cached Medicine Technology:Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis 2Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 2Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 3Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 4Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 5Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 6Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients 7
(Date:1/22/2015)... Deer Path of Huntley -- a BMA ... Hour from 3 p.m. to 4 p.m. on Feb. 13. , ... Illinois, serves adults with physical disabilities between the ages of 22 ... treats, games and sweetheart-themed karaoke. , For more information about the ...
(Date:1/22/2015)... Liberty University has received accreditation for its ... the Council for Accreditation of Counseling & Related Educational ... Center for Counseling & Family Studies , is under the ... new School of Behavioral Sciences. Prior to the formation of ...
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... body of the release., SAN DIEGO -- The ... chronic lymphocytic leukemia (CLL) has unearthed several new altered ... that could potentially help doctors predict whether an individual ... years, say scientists from Dana-Farber Cancer Institute and the ...
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... Scientists have discovered a new way to target cancer through ... The findings, published today [12 Dec] in the journal ... by producing their own blood vessels. Cancer cells ... blood vessels grow, helping deliver oxygen and sugars to the ...
... Dec. 12 (HealthDay News) -- Severe side effects may be ... taking drugs that can help prevent a tumor,s return, a ... gap between what these breast cancer patients tell their doctors ... to the study authors from Northwestern University in Chicago. ...
... , DETROIT Researchers at Henry Ford Hospital have found ... only patients consistently took their medication as prescribed. Moreover, ... at least 75 percent of their prescribed dose, according to ... on the onset and degree of symptoms. Henry Ford ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Massive DNA search uncovers new mutations driving blood cancer 2Health News:Massive DNA search uncovers new mutations driving blood cancer 3Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:Scientists discover new way to target cancer 2Health News:Side Effects Cause Many Older Women to Drop Breast Cancer Drugs 2Health News:Improved medication use could reduce severe asthma attacks 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products: